selective factor B serine protease inhibitor

orally available, retinal barrier penetrant

J. Med. Chem., Feb. 19, 2020

Novartis (NIBR), Cambridge, MA


February’s molecule, the Novartis factor B inhibitor LNP023, targets the serine protease factor B (FB), a key node in the complement system. The complement part of the innate immune system is…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: